Duality Advisers’s Allogene Therapeutics ALLO Stock Holding History

Duality Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,912	Closed	-$263K	–	590
2022 Q1	$263K	Sell	28,912 -80,218	-74%	-$836K	0.03%	571
2021 Q4	$1.63M	Buy	+109,130	New	+$1.93M	0.18%	213
2021 Q3	–	Sell	-37,372	Closed	-$975K	–	512
2021 Q2	$975K	Buy	+37,372	New	+$1.07M	0.09%	339
2021 Q1	–	Sell	-82,662	Closed	-$2.09M	–	525
2020 Q4	$2.09M	Buy	+82,662	New	+$2.69M	0.16%	203

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Duality Advisers's ALLO Position: Q2 2022 in Review

Duality Advisers sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 28,912 shares — an estimated $263K sold.

Duality Advisers first reported a position in ALLO in Q4 2020 and held it in 4 quarters. The position peaked at $2.09M in Q4 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

Duality Advisers reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
Duality Advisers sold 28,912 Allogene Therapeutics shares in Q2 2022, an estimated $263K.
Duality Advisers first reported a position in Allogene Therapeutics in Q4 2020 and held it in 4 quarters.
Duality Advisers's Allogene Therapeutics position peaked at $2.09M in Q4 2020.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.